Navigation Links
GFX: Wrinkle-Killer or Botox(R) Hit-Man?
Date:3/10/2008

NORTH DALLAS, Texas and PLANO, Texas, March 10 /PRNewswire/ -- Tired of frequent Botox injection visits? GFX might be the long-term wrinkle solution for you!

Newly-FDA approved GFX (Glabella Furrow Relaxation) recently arrived in North Texas and is already making waves -- radiofrequency waves, to be exact -- in select aesthetic centers and cosmetic surgery offices. GFX is a unique technological advancement in facial rejuvenation that offers long-term relaxation of overactive 'frown' muscles; a proposition likely to thrill many long-time Botox users, but one that targets the Botox(R) empire for a kill-shot where it would hurt the most ... right between the eyebrows.

Botox(R) muscle-relaxing injection results typically last from 3 to 4 months on average, while the results of one in-office GFX (sometimes called 'No-tox') treatment averages 18 months or longer. According to Jeffrey Adelglass, M.D., F.A.C.S., a popular North Dallas area cosmetic surgeon who has had plenty of experience working with a variety of cosmetic injectables, treatment of the glabella area alone constitutes approximately 65% -- the lion's share -- of his Botox injections. While his GFX patients might still receive periodic Botox(R) injections in other forehead areas (GFX is currently only FDA-approved for the glabella), sometimes keeping the glabella relaxed can, over time, soften wrinkles in other forehead areas, as well. An observed effect of the treatment has been that eyebrows gradually tend to become more elevated and horizontal forehead lines reduced, potentially eliminating the need for elective surgery or neurotoxin injections entirely for some aesthetic patients.

How does GFX work? This minimally-invasive, in-office procedure utilizes a specified dose of radiofrequency (RF) thermal energy, delivered through an insulated bipolar needle inserted near the eyebrows, on either side of the forehead. First, the doctor delivers a stimulating pulse through the needle tome and recovery.

Contact:

Pamela Fox, Director of Communications, 972-620-3223


'/>"/>
SOURCE SKINTASTIC Medical and Surgical Rejuvenation Center
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AAFPRS Speaks to the Safety of BOTOX(R) Cosmetic
2. American Society for Dermatologic Surgery Supports Current Labeling of Allergans Botox(R) Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... San Diego, CA (PRWEB) , ... March 28, 2017 , ... ... and turtlenecks from the daily wardrobe. However, for those self-conscious about a double chin, ... believe they have the ideal solution. , “For most people, a double chin ...
(Date:3/28/2017)... ... March 28, 2017 , ... Neurotechnology , ... biometric time and attendance tracking products: the new NCheck Cloud Bio Attendance cloud-based ... Attendance uses biometric face recognition to enable users to check in and out ...
(Date:3/28/2017)... ... March 28, 2017 , ... Columbus OH. Dr. Justin ... one of few medical professionals in the country to sit on the 2017 National ... Aesthetics, in just 2 years Dr. Harper helped propel the clinic from a small ...
(Date:3/28/2017)... Atlantic City, NJ (PRWEB) , ... March 28, ... ... annual American Camp Association’s Tri-State Camp Conference in Atlantic City March 13-16, was ... partners, and their team of professional staff discussed strategies for preventing outbreaks among ...
(Date:3/28/2017)... St. Louis, MO (PRWEB) , ... March 28, ... ... high levels of job satisfaction in their profession as their value increases in ... a company that provides resources such as job boards, career fairs, and candidate ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... United Kingdom and  BOSTON , March 28, ... Linguamatics today announced a partnership with ... The agreement allows pharmaceutical companies to extract key ... I2E text mining technology. The ... of the top 20 global pharmaceutical companies. The ...
(Date:3/28/2017)... , March 28, 2017  AcelRx Pharmaceuticals, Inc. ... the development and commercialization of innovative therapies for ... the European Medicines Agency (EMA) has notified the ... mcg) Marketing Authorisation Application (MAA) has passed validation, ... is underway. The MAA for ARX-04 (known as ...
(Date:3/28/2017)... 28, 2017 The global ... 8.0 billion by 2025, according to a new study ... infectious diseases and cancer is expected to upsurge the ... over the coming years. In addition, higher number of ... allogenic stem cell therapy, due to adverse effects caused ...
Breaking Medicine Technology: